Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

(Bloomberg) -- Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

The pandemic accelerated Moderna's evolution into a commercial-stage biotech, and we expect that the firm's ramp-up in manufacturing and clinical know-how will pave the way for faster timelines ...

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

2 In it, Bancel writes, “As we reflect on 2024, it is clear that the past year brought formidable challenges for Moderna along with significant advances, particularly for our development pipeline. It ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

Moderna attributed that commercial haul to more than $3 billion in Spikevax sales and a “minimal” contribution from mRESVIA, which was approved by the FDA in May. In an annual shareholder ...